Garrya

Garrya: A Comprehensive Reference

1. Identity and Botanical Classification

Genus and family: Garrya is a genus of flowering plants placed in the family Garryaceae, order Garryales. Garryales is placed in the asterid clade at the base of the euasterid I group of the Angiosperm Phylogeny Group (APG III) botanical classification system. The family Garryaceae encompasses two genera: the North and Central American Garrya and the East Asian Aucuba, with molecular studies confirming Garrya as sister to Aucuba.

Number of species and distribution: The genus Garrya includes approximately 17 species of evergreen shrubs or small trees, most native to western North America from Washington to Baja California, with outliers in Central America and the Caribbean. There are about 18 species of Garrya in North and Central America and the Caribbean, with 8 species from the U.S., mostly limited to the southwest and southern Pacific Coast.

Medically relevant species: The species most commonly associated with traditional medicinal use and phytochemical research are:

• Garrya elliptica Douglas ex Lindl. — Coast silk-tassel, silk tassel bush, or wavyleaf silktassel. The leaf of Garrya elliptica is the primary plant part used; the shrub is native to California and southern Oregon.
• Garrya fremontii Torr. — Also known as bearbrush, mountain silktassel, green-leaf silktassel, California feverbush, quinine bush, flannel bush, or upland silktassel bush.
• Garrya veatchii Kellogg — The principal source of the named Garrya alkaloids in chemical research.
• Garrya flavescens S. Wats. — Ashy silktassel; also called silktassel, quinine bush, or yellowleaf silktassel.
• Garrya wrightii Torr. — Wright's silktassel, a species also confirmed to contain crystalline alkaloids.

Morphology: Garryaceae are evergreen shrubs and trees with opposite, nonstipulate leaves that are basally joined. Garrya is distinguished from Aucuba by its dioecious (separate male and female) inflorescences and simple, opposite leaves. In G. elliptica specifically, the leaves are shiny and leathery with woolly hairs on the undersides; they are opposite, elliptical to ovate with a tough leathery feel, glossy green on top but paler and duller beneath. The dioecious flowers are concentrated in inflorescences which cascade downward as aments; while it manifests separate male and female plants, the pendant male catkins are much more showy and are grey-green and up to 30 cm long, while the female ones are shorter and silver-grey. The ripened purplish-black fruit is about 1 cm in diameter, with a hard desiccated coating but is rather fleshy on the interior.

Common names: The genus as a whole is most widely called silk tassel or tassel bush, derived from the characteristic pendant catkins. Individual species carry common names including bearbrush, mountain silktassel, green-leaf silktassel, California feverbush, quinine bush, and flannel bush.

Etymology: The genus Garrya honors Nicholas Garry (1782–1856), deputy-governor of the Hudson Bay Company, a friend and benefactor of David Douglas (who introduced the plant to the gardeners of the British Isles) that assisted on Douglas's plant-collecting expeditions to the Pacific Northwest; he is also honored in the name of the Oregon white oak, Quercus garryana. The specific epithet elliptica is from the Greek word for "twice as long as broad," or "oblong with rounded ends," and refers to the shape of the leaves.

Common preparations used medicinally: The twigs and leaves are the parts used for making medicine. The leaves can be made into tea, either fresh or dried. Garrya leaf tastes bitter with an odd smell; when made into a tincture, the resulting color is a mixture of black, gray, and blue. The bark is also employed, as reflected in early pharmaceutical and phytochemical investigations of bark-derived alkaloids.

2. History of Botanical Discovery and Introduction

Douglas encountered tassel bush (Garrya elliptica) in California in 1832, and like Garry oak, also named this small tree or shrub for Nicholas Garry of the Hudson's Bay Company, in appreciation for his assistance. Douglas introduced silk tassel bush to the UK in 1828, where it became a horticultural novelty. The plant was regarded as a remarkable botanical find: Dr. Lindley considered Garrya the greatest botanical curiosity in all of David Douglas's collection.

3. Traditional and Historical Use

3.1 Indigenous North American Use

Indigenous peoples of California, including the Pomo and Kashaya, have traditionally used infusions of Garrya elliptica leaves as an emmenagogue to induce menstruation and alleviate associated pains. The leaves are intensely bitter and were used as an antiperiodic, making them a historical substitute for quinine in treating fevers and as a general febrifuge.

An infusion of the leaves of Garrya flavescens was taken for gonorrhea, as a laxative, and for stomachaches by southwestern Native Americans.

Formerly medicinal, the bark contains at least five alkaloids, including delphinine, which is otherwise known only from Aconitum and Delphinium. The Paiute Indians smoked it with tobacco in the medicine pipe as a kinnikinnick.

The Yurok Native American tribe would use tools made from this wood to scrape mussels off of rocks.

3.2 Early Settler and Frontier Medicine

Early settlers used the leaves of G. fremontii to make a tonic, for fevers, and as a substitute for quinine. This use earned the plant its common name "quinine bush" or "feverbush." Garrya leaf has been used for centuries as a remedy for fevers, malaria, and other periodic diseases, probably due to its intense bitter taste.

3.3 Scope of Traditional Preparations and Indications

Across different cultures and traditions, the plant was primarily applied in the following areas:

• Menstrual and uterine conditions: Garrya leaf was used in traditional contexts as a remedy for menstrual pains and as a uterine stimulant.
• Gastrointestinal complaints: The leaves and bark of Garrya were commonly utilized to address digestive disturbances, such as cramps, nausea, and diarrhea. Garrya flavescens has been traditionally used to treat gastrointestinal spasms.
• Fevers and malaria-like illnesses: The bitter, antiperiodic use paralleled that of cinchona-bark quinine, as described above.
• Topical use: Garrya leaf is also reported to be used externally for wounds, painful inflammation, cuts, and other minor scratches and bruises.

4. Key Constituents and Active Compounds

4.1 Diterpenoid Alkaloids

The most pharmacologically investigated compounds in Garrya are its C20-diterpenoid alkaloids. Diterpenoid alkaloids are isolated from plants of the genera Aconitum, Delphinium, and Garrya and are classified according to their chemical structures as C18-, C19-, or C20-diterpenoid alkaloids.

Early systematic chemical work described the alkaloidal variation across the genus: Six species of Garrya were examined for their alkaloidal content. G. flavescens contained no alkaloids, while G. fremontii and G. buxifolia yielded amorphous, basic, nitrogenous residues which did not form crystalline salts. G. elliptica, G. veatchii, and G. wrightii, on the other hand, all contained alkaloids which were isolated as crystalline hydrochlorides.

The principal named alkaloids isolated from the genus are:

• Garryine and Veatchine: Two crystalline substances were isolated from the bark of G. veatchii; the proposed names and provisional empirical formulas for these two substances are (a) garryine [C₂₂H₃₂O₂N·H₂O] and (b) veatchine (C₂₂H₃₂O₂N). Garryine is a hexacyclic veatchine-type C20-diterpenoid alkaloid originally isolated from the bark of Garrya veatchii Kellogg; this complex natural product serves as a valuable reference standard in phytochemical research and the study of diterpenoid alkaloid biosynthesis.
• Cuauchichicine and Garryfoline: Additional alkaloids investigated pharmacologically in animal studies (see below).
• Delphinine: Some Garrya species contain highly toxic alkaloids similar to those of Aconitum (monkshood) and Delphinium (larkspur) in the distantly related Ranunculaceae.

Structural chemistry: By means of hydrogenation, oxidation, and isomerization experiments it has been established that the chemistry of veatchine and garryine parallels the chemistry of atisine and isoatisine. In the biosynthetic process, the nitrogen atom of β-aminoethanol, methylamine, or ethylamine is linked to C-19 and C-20 in the C20-diterpenoid skeleton and to C-17 and C-19 in the C19-diterpenoid skeleton, to form a substituted piperidine ring system.

Some progress in understanding the Aconite alkaloid class was achieved when it was recognized that a third genus, Garrya, yields especially simple and easily available bases which undoubtedly belong, according to their chemical properties, to the class of aconite alkaloids.

4.2 Flavonoids and Polyphenols

More recently, a 2026 peer-reviewed phytochemical study (published in Plants, MDPI) characterized the flavonoid content of G. flavescens in detail. Phytochemical profiling using LC-HRMS and HPLC identified rutin as a primary bioactive component, present at an exceptionally high concentration of 9,309 μg/g. Rutin is a flavonol glycoside (quercetin-3-rutinoside) recognized for antioxidant and anti-inflammatory properties in a broad phytochemical literature.

4.3 Other Constituents

Preliminary research has identified the presence of bioactive alkaloids and flavonoids in Garrya, compounds known for their antioxidant and anti-inflammatory properties. The intensely bitter taste of the leaves — which historically drove their comparison to quinine — is consistent with the presence of nitrogen-containing diterpenoid alkaloids bearing a bitter sensory profile.

5. Mechanisms of Action

5.1 Pharmacological Action of Garrya Alkaloids: Animal Data

The most direct published pharmacological investigation of Garrya alkaloids was conducted in animal models. Four Garrya alkaloids — garryine, veatchine, cuauchichicine, and garryfoline — were studied with respect to toxicity and their action on smooth muscle, blood pressure, and respiration. In mice the toxic signs of all four Garrya alkaloids were similar. None of the alkaloids had any significantly potent action on smooth muscle organs. Garryfoline seemed to have a weak antihistaminic and anticholinergic action.

In the anesthetized cat, the Garrya alkaloids briefly lowered the blood pressure. Large doses caused respiratory failure. No action was observed on the uterus and intestines in situ.

This finding is particularly significant because it reveals a direct contradiction between animal pharmacology and the primary traditional use: despite the plant's historical reputation as an antispasmodic and emmenagogue, controlled animal studies found no measurable action on smooth muscle (uterus or intestine) from the isolated alkaloids at doses that did not cause toxicity.

5.2 Neuroinflammatory and Signaling Pathways: Cell-Based Data

A 2026 in-vitro study (published in Plants, MDPI) investigated G. flavescens extract in activated microglial cell lines: In BV-2 microglial and RAW 264.7 cells, G. flavescens treatment significantly suppressed the expression of pro-inflammatory cytokines and mediators in a dose-dependent manner. Mechanistic studies revealed that G. flavescens specifically modulated the ERK signaling pathway. Furthermore, Seahorse XF analysis demonstrated that G. flavescens restored mitochondrial homeostasis by reducing basal respiration and proton leak while significantly enhancing spare respiratory capacity.

5.3 Diterpenoid Alkaloids and the Central Nervous System

The unique pharmacological impacts of diterpenoid alkaloids (DAs) on the central nervous system (CNS) encouraged scientists to seek new lead compounds. Several authors have previously reviewed the recent evidence associated with DAs' diversity, toxicity, biosynthesis, pharmacokinetics, structure–activity (or toxicity) relationship, and their analgesic, cytotoxicity, anti-inflammatory, and antimicrobial activities. These alkaloids originate through the amination reaction of tetra- or pentacyclic diterpenoids; the main chemical characteristics of DAs are their heterocyclic systems containing β-aminoethanol, methylamine, or ethylamine functionality.

6. Scientific Evidence by Area of Use

6.1 Antispasmodic and Smooth-Muscle Effects

Evidence level: Animal/in-vitro only; results negative for the isolated alkaloids

The traditional antispasmodic reputation of Garrya has not been validated by controlled scientific study of the pure alkaloids. None of the four investigated Garrya alkaloids had any significantly potent action on smooth muscle organs in animal experiments. No action was observed on the uterus and intestines in situ. Animal studies suggest that extracts of Garrya may possess spasmolytic effects, supporting its traditional use for cramping and digestive issues, but these claims appear to reflect whole-extract rather than purified-alkaloid studies, and no controlled human clinical data exist. No clinical trials, systematic reviews, or human pharmacological studies on Garrya's antispasmodic activity could be identified in the peer-reviewed literature.

6.2 Antipyretic / Antiperiodic (Fever and Malaria-like Conditions)

Evidence level: Traditional use only; no modern clinical evidence

The use of G. elliptica and G. fremontii as a quinine substitute is historically well-documented across indigenous and frontier contexts. The leaves are intensely bitter and were used as an antiperiodic, making them a historical substitute for quinine in treating fevers and as a general febrifuge. However, no modern clinical studies have investigated whether Garrya extracts have genuine antimalarial or antipyretic activity. The bitter taste rationale (paralleling cinchona bark) is ethnopharmacological in character and has not been subjected to pharmacological confirmation in controlled studies.

6.3 Menstrual and Uterine Effects (Emmenagogue)

Evidence level: Traditional use only; pharmacological animal studies contradict the mechanism

Indigenous peoples of California, including the Pomo and Kashaya, have traditionally used infusions of Garrya elliptica leaves as an emmenagogue to induce menstruation and alleviate associated pains. However, the pharmacological study of isolated Garrya alkaloids found no action on the uterus in situ in animal models, calling into question whether the alkaloids themselves are the active mediators of the traditionally observed effects. No human clinical studies exist.

6.4 Anti-inflammatory and Neuroprotective Effects

Evidence level: Preliminary in-vitro only (cell lines); no animal in-vivo or human data

The most current scientific data on Garrya come from a 2026 cell-culture study of G. flavescens. This study aimed to characterize the bioactive constituents of G. flavescens and evaluate its anti-inflammatory and metabolic regulatory effects in lipopolysaccharide-activated microglia. Phytochemical profiling using LC-HRMS and HPLC identified rutin as the primary bioactive component, present at an exceptionally high concentration (9,309 μg/g). The study found dose-dependent suppression of pro-inflammatory mediators, ERK pathway modulation, and restoration of mitochondrial function in cell lines. These are cell-culture findings only; no animal in-vivo or human clinical replication has been published. The evidence must be characterized as very preliminary and hypothesis-generating.

6.5 Potential Cytotoxic Activity of Related Diterpenoid Alkaloids

Evidence level: In-vitro studies on related compounds; not specific to Garrya-derived molecules in clinical context

The extreme toxicity of certain diterpenoid compounds, such as aconitine, has prompted thorough investigation of how structural features affect their bioactivities. Such research encourages an understanding of the relationships between structure and cytotoxic activity of aconitine and related compounds. Studies have demonstrated effects of various naturally occurring and semi-synthetic C19- and C20-diterpenoid alkaloids on the growth of human malignant glioma cell lines. None of these studies has used Garrya-derived alkaloids specifically in clinical or human contexts; any cytotoxic interest relates to the broader diterpenoid alkaloid class.

7. Body Systems and Health Areas Associated with Garrya

Based on the documented traditional uses and available scientific investigation, Garrya has been associated with the following body systems:

• Reproductive system: Historical use as an emmenagogue, uterine stimulant, and remedy for menstrual cramping, primarily in indigenous California traditions.
• Gastrointestinal system: Early records highlighting its use as a remedy for digestive disturbances, including cramps, nausea, and diarrhea.
• Immune / inflammatory system: Preliminary cell-line data suggesting suppression of microglial pro-inflammatory cytokines via ERK pathway modulation.
• Central nervous system: Diterpenoid alkaloids found in Garrya have long been a focus of research attention due to their numerous intricate structures and diverse biological activities, especially in the central nervous system.
• Cardiovascular system: Animal pharmacology showed a brief blood-pressure-lowering effect of Garrya alkaloids in cats, though this was not observed at non-toxic doses.
• Infectious disease / febrile states: Traditional use as an antiperiodic and fever remedy, without modern pharmacological confirmation.

8. Dosage Forms and Dosages Reported in Sources

No standardized human clinical dosage for any Garrya preparation has been established in peer-reviewed literature, pharmacopeial monographs, or institutional health-body guidance. The following are the forms and contextual dosage information that can be sourced:

• Leaf infusion (tea): The twigs and leaves are the parts most commonly used for making medicine; the leaves can also be made into tea, either fresh or dried. No standardized quantity per dose is reported in the peer-reviewed literature.
• Tincture: The plant's bark and leaves were commonly prepared as teas or tinctures in traditional herbal medicine. No concentration, dose, or frequency data derived from clinical study sources are available.
• Bark decoction: Used historically for alkaloid-containing preparations, given that crystalline alkaloids are concentrated in the bark of species such as G. veatchii and G. elliptica.
• In-vitro study extract concentration: The 2026 G. flavescens cell-line study administered extract in a dose-dependent manner in BV-2 and RAW 264.7 cell lines, with rutin content quantified at 9,309 μg/g of dry extract, but no human-equivalent dosages were extrapolated.

No government body (NIH, NCCIH, EMA, ESCOP), pharmacopeia, or systematic review has established or endorsed a specific therapeutic dosage for any Garrya preparation in humans.

9. Safety Considerations and Toxicology

9.1 Alkaloid Toxicity

Some Garrya species contain highly toxic alkaloids similar to those of Aconitum (monkshood) and Delphinium (larkspur). This comparison is toxicologically significant: aconitine-type diterpenoid alkaloids are among the most acutely toxic naturally occurring compounds, associated with cardiac arrhythmia and neurotoxicity.

In mice, the toxic signs of all four Garrya alkaloids studied (garryine, veatchine, cuauchichicine, and garryfoline) were similar. In the anesthetized cat, the Garrya alkaloids briefly lowered blood pressure. Large doses caused respiratory failure. These animal toxicology data indicate a narrow margin between pharmacologically active and acutely toxic doses for the pure alkaloids.

9.2 Inter-Species Variability in Alkaloid Content

The alkaloid content varies substantially by species. G. flavescens contained no alkaloids in the early systematic study, while G. fremontii and G. buxifolia yielded only amorphous, basic nitrogenous residues which did not form crystalline salts. By contrast, G. elliptica, G. veatchii, and G. wrightii yielded fully crystalline, pharmacologically active alkaloids. This means that the toxicological risk varies considerably across species in the genus, and preparations sourced from high-alkaloid species carry greater risk.

9.3 Processing and Toxicity Reduction

In traditional Chinese and Japanese medicine, for centuries, plants containing diterpenoid alkaloids have conventionally been used after being processed into less toxic products. This principle — of processing to reduce toxicity before use — has not been formally documented for Garrya preparations in North American indigenous contexts, but the parallel with closely related alkaloid-bearing genera is pharmacologically relevant.

9.4 Absence of Regulatory Status and Clinical Safety Data

No regulatory agency (FDA, EMA, Health Canada) has evaluated or approved any Garrya preparation as a dietary supplement, herbal medicine, or drug. No human clinical safety trials have been conducted or published. The plant has no entry in major pharmacopeias (USP, European Pharmacopoeia) or institutional monographs (WHO, ESCOP, German Commission E). Scientific investigation into Garrya's efficacy is in its early stages.

9.5 Contraindications Implied by Traditional and Pharmacological Data

Given the documented historical use of Garrya leaf infusions as a uterine stimulant and emmenagogue, and the botanical relationship of its alkaloids to classes associated with uterine and cardiovascular effects in toxicological studies, pregnancy represents an area of particular concern based on traditional indication data. No formal clinical teratogenicity or contraindication data exist.

10. Current Status in Herbal Medicine

In contemporary herbal practice, Garrya — primarily G. elliptica — is a minor, uncommon botanical ingredient. It appears in some Western herbalism contexts for antispasmodic and menstrual applications, but its use is not widespread, it lacks pharmacopeial recognition, and it has attracted only modest modern scientific attention compared to related genera such as Aconitum. The most substantial recent research (2026) involves G. flavescens as an anti-neuroinflammatory candidate in cell-based models, representing a new direction distinct from historical applications. The overall body of evidence for any therapeutic claim in humans remains absent or extremely preliminary.

References

• Britannica — Garryales: Classification and Description
• Oneto, J.F. (1946). The Alkaloids of Species of Garrya. I. Isolation of Alkaloids. Journal of the American Pharmaceutical Association, 35: 204–207.
• Wiesner, K. et al. (1952). Garrya Alkaloids. I. The Structure of Garryine and Veatchine. Canadian Journal of Chemistry.
• Armstrong et al. (1954). Garrya Alkaloids. III. The Skeletal Structure of the Garrya Alkaloids. Journal of the American Chemical Society, 76(23): 6068–6073.
• Springer — Recent Progress in the Chemistry of the Aconite-Garrya Alkaloids
• Grokipedia — Garrya elliptica (botanical and ethnobotanical overview)
• PMC — Neuropharmacological Potential of Diterpenoid Alkaloids (2023)
• PMC — Cytotoxic Effects of Diterpenoid Alkaloids Against Human Cancer Cells (2019)
• Yang, H.-J. et al. (2026). Anti-Inflammatory Properties of Garrya flavescens: Phytochemical Profiling and Mitigation of LPS-Induced Neuroinflammation via ERK Signaling and Mitochondrial Modulation. Plants, 15(9): 1319.
• ResearchGate — Spasmolytic Botanicals: Relaxing Smooth Muscle with Herbs (references pharmacological action of Garrya alkaloids)
• Native Plants PNW — Fremont Silktassel, Garrya fremontii
• Oregon State University — Garrya fremontii (Landscape Plants)
• Southwest Desert Flora — Garrya flavescens, Ashy Silktassel
• NC State Extension — Garrya elliptica (Ethnobotany and Plant Description)
• Natural Wellbeing — Garrya Leaf (traditional preparations overview)
• BenchChem — Garryine: Chemical Profile and Total Synthesis
• VanDusen Botanical Garden — The Legacy of Plant Explorer David Douglas
• ScienceDirect — Chapter 22: The Diterpenoid Alkaloids from Aconitum, Delphinium, and Garrya Species